Abstract
Current antiestrogen therapy for breast cancer is limited by the mixed estrogenic and antiestrogenic activity of selective estrogen receptor modulators. Here we show that the function of zinc fingers in the estrogen receptor DNA-binding domain (DBD) is susceptible to chemical inhibition by electrophilic disulfide benzamide and benzisothiazolone derivatives, which selectively block binding of the estrogen receptor to its responsive element and subsequent transcription. These compounds also significantly inhibit estrogen-stimulated cell proliferation, markedly reduce tumor mass in nude mice bearing human MCF-7 breast cancer xenografts, and interfere with cell-cycle and apoptosis regulatory gene expression. Functional assays and computational analysis support a molecular mechanism whereby electrophilic agents preferentially disrupt the vulnerable C-terminal zinc finger, thus suppressing estrogen receptor–mediated breast carcinoma progression. Our results provide the proof of principle for a new strategy to inhibit breast cancer at the level of DNA binding, rather than the classical antagonism of estrogen binding.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Jordan, V.C. Antiestrogenic action of raloxifene and tamoxifen: today and tomorrow. J. Natl. Cancer Inst. 90, 967– 971 (1998).
Brzozowski, A.M. et al. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 389, 753– 758 (1997).
Dutertre, M. & Smith, C.L. Molecular mechanisms of selective estrogen receptor modulator (SERM) action. J. Pharmacol. Exp. Ther. 295, 431– 437 (2000).
Shang, Y. & Brown, M. Molecular determinants for the tissue specificity of SERMs. Science 295, 2465– 2468 (2002).
Shiau, A.K. et al. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 95, 927– 937 (1998).
Tsai, M.J. & O'Malley, B.W. Molecular mechanisms of action of steroid/thyroid receptor superfamily members. Annu. Rev. Biochem. 63, 451– 486 (1994).
Beato, M., Herrlich, P. & Schutz, G. Steroid hormone receptors: many actors in search of a plot. Cell 83, 851– 857 (1995).
McDonnell, D.P. & Norris, J.D. Connections and regulation of the human estrogen receptor. Science 296, 1642– 1644 (2002).
Wang, L.H. et al. Activation of estrogen receptor blocks interleukin-6-inducible cell growth of human multiple myeloma involving molecular cross-talk between estrogen receptor and STAT3 mediated by co-regulator PIAS3. J. Biol. Chem. 276, 31839– 31844 (2001).
Schwabe, J.W.R., Chapman, L., Finch, J.T. & Rhodes, D. The crystal structure of the estrogen receptor DNA-binding domain bound to DNA: how receptors discriminate between their response elements. Cell 75, 567– 578 (1993).
Schwabe, J.W., Neuhaus, D. & Rhodes, D. Solution structure of the DNA-binding domain of the oestrogen receptor. Nature 348, 458– 461 (1990).
Maynard, A.T. & Covell, D.G. Reactivity of zinc finger cores: analysis of protein packing and electrostatic screening. J. Am. Chem. Soc. 123, 1047– 1058 (2001).
Whittal, R.M. et al. Preferential oxidation of zinc finger 2 in estrogen receptor DNA-binding domain prevents dimerization and, hence, DNA binding. Biochemistry 39, 8406– 8417 (2000).
Rice, W.G. & Turpin, J.A. Virus-encoded zinc fingers as targets for antiviral chemotherapy. Rev. Med. Virol. 6, 187– 199 (1996).
Huang, M. et al. Anti-HIV agents that selectively target retroviral nucleocapsid protein zinc fingers without affecting cellular zinc finger proteins. J. Med. Chem. 41, 1371– 1381 (1998).
Maynard, A.T., Huang, M., Rice, W.G. & Covell, D.G. Reactivity of the HIV-1 NCp7 zinc finger domains from the perspective of density-functional theory. Proc. Natl. Acad. Sci. USA 95, 11578– 11583 (1998).
Dickson, R.B. McManaway, M.E. & Lippman, M.E. Estrogen-induced factors of breast cancer cells partially replace estrogen to promote tumor growth. Science 232, 1540– 1543 (1986).
Urano, T. et al. Efp targets 14-3-3 sigma for proteolysis and promotes breast tumour growth. Nature 417, 871– 875 (2002).
Shafie, S.M. & Grantham, F.H. Role of hormones in the growth and regression of human breast cancer cells (MCF-7) transplanted into athymic nude mice. J. Natl. Cancer Inst. 67, 51– 56 (1981).
Wang, W., Dong, L., Saville, B. & Safe, S. Transcriptional activation of E2F1 gene expression by 17β-estradiol in MCF-7 cells is regulated by NF-Y-Sp1/estrogen receptor interactions. Mol. Endocrinol. 13, 1373– 1387 (1999).
Ngwenya, S. & Safe, S. Cell context-dependent differences in the induction of E2F-1 gene expression by 17β-estradiol in MCF-7 and ZR-75 cells. Endocrinology 144, 1675– 1685 (2003).
Warri, A.M., Huovinen, R.L., Laine, A.M., Martikainen, P.M. & Harkonen, P.L. Apoptosis in toremifene-induced growth inhibition of human breast cancer cells in vivo and in vitro. J. Natl. Cancer Inst. 85, 1412– 1418 (1993).
Tummino, P.J. et al. The in vitro ejection of zinc from human immunodeficiency virus (HIV) type 1 nucleocapsid protein by disulfide benzamides with cellular anti-HIV activity. Proc. Natl. Acad. Sci. USA 93, 969– 973 (1996).
Bernstein, F.C. et al. The Protein Data Bank: a computer-based archival file for macromolecular structures. J. Mol. Biol. 112, 535– 542 (1977).
Predki, P.F. & Sarkar, B. Effect of replacement of “zinc finger” zinc on estrogen receptor DNA interactions. J. Biol. Chem. 267, 5842– 58466 (1992).
Cano-Gauci, D.F. & Sarkar, B. Reversible zinc exchange between metallothionein and the estrogen receptor zinc finger. FEBS Lett. 386, 1– 4 (1996).
Lee, S. & Maret, W. Redox control of zinc finger proteins: mechanisms and role of gene regulation. Antioxid. Redox Signal. 3, 531– 534 (2001).
Liang, X. et al. Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Mol. Cell Endocrinol. 146, 151– 161 (1998).
Vigushin, D.M. et al. Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo. Clin. Cancer Res. 7, 971– 976 (2001).
Yoshida, M., Horinouchi, S. & Beppu, T. Trichostatin A and trapoxin: novel chemical probes for the role of histone acetylation in chromatin structure and function. BioEssays, 17, 423– 430 (1995).
Matthews, J.R., Botting, C.H., Panico, M., Morris, H.R. & Hay R.T. Inhibition of NF-κB DNA binding by nitric oxide. Nucleic Acids Res. 24, 2236– 2242 (1996).
Biswas, D.K., Cruz, A.P., Gansberger, E. & Pardee, A.B. Epidermal growth factor-induced nuclear factor κ B activation: a major pathway of cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc. Natl. Acad. Sci. USA 97, 8542– 8547 (2000).
Kyprianou, N., English, H.F., Davidson, N.E. & Isaacs, J.T. Programmed cell death during regression of the MCF-7 human breast cancer following estrogen ablation. Cancer Res. 51, 162– 166 (1991).
Zhang, S.Y. et al. E2F-1: a proliferative marker of breast neoplasia. Cancer Epidemiol. Biomarkers Prev. 9, 395– 401 (2000).
Weinberg, R.A. E2F and cell proliferation: a world turned upside down. Cell 85, 457– 459 (1996).
Yamasaki, L. et al. Tumor induction and tissue atrophy in mice lacking E2F-1. Cell 85, 537– 548 (1996).
Pierce, A.M. et al. Increased E2F1 activity induces skin tumors in mice heterozygous and nullizygous for p53. Proc. Natl. Acad. Sci. USA 95, 8858– 8863 (1998).
Truchet, I. et al. Interconnections between E2-dependent regulation of cell cycle progression and apoptosis in MCF-7 tumors growing on nude mice. Exp. Cell Res. 254, 241– 248 (2000).
White, E. Life, death, and the pursuit of apoptosis. Genes Dev. 10, 1– 15 (1996).
Morgenbesser, S.D., Williams, B.O., Jacks, T. & DePinho, R.A. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371, 72– 74 (1994).
Almasan, A. et al. Deficiency of retinoblastoma protein leads to inappropriate S-phase entry, activation of E2F-responsive genes, and apoptosis. Proc. Natl. Acad. Sci. USA 92, 5436– 5440 (1995).
Laity, J.H., Lee, B.M. & Wright, P.E. Zinc finger proteins: new insights into structural and functional diversity. Curr. Opin. Struct. Biol. 11, 39– 46 (2001).
Parr, R.G., Szentpaly, L. & Liu, S. Electrophilicity index. J. Am. Chem. Soc. 121, 1922– 1924 (1999).
Ju, Y.H., Doerge, D.R., Allred, K.F., Allred, C.D. & Helferich, W.G. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 62, 2474– 2477 (2002).
Bandyopadhyay, A. et al. Antitumor activity of a recombinant soluble β-glycan in human breast cancer xenograft. Cancer Res. 62, 4690– 4695 (2002).
Acknowledgements
We are grateful to J. Oppenheim and J.A. Turpin for critical review of the manuscript; M.R. Anver, H. Zhou and K. Rogers for help with pathology; M.G. Hollingshead and W. Ma for help with animal experiments; and R. Evans and T. Chen for providing plasmids. This project has been funded in whole or in part with Federal funds from the National Cancer Institute and the National Institutes of Health, under Contract NO1-CO-12400.
Author information
Authors and Affiliations
Corresponding authors
Ethics declarations
Competing interests
The authors declare no competing financial interests.
Rights and permissions
About this article
Cite this article
Wang, L., Yang, X., Zhang, X. et al. Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor. Nat Med 10, 40–47 (2004). https://doi.org/10.1038/nm969
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm969
This article is cited by
-
Antineoplastic effects of an Aurora B kinase inhibitor in breast cancer
Molecular Cancer (2010)
-
Transcription factor AP-2 and monoaminergic functions in the central nervous system
Journal of Neural Transmission (2005)
-
Articles selected in February 2004
Breast Cancer Research (2004)